Abstract Creutzfeldt-Jakob disease
Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of invariably fatal neurodegenerative disorders affecting humans and animals (Aguzzi and Heikenwalder 2006) ; the number of such disorders is Electronic supplementary material The online version of this article (doi:10.1007/s10571-010-9529-5) contains supplementary material, which is available to authorized users.
growing (Watts et al. 2006; Mallucci and Collinge 2004) . At least four novel prion diseases, including human variant Creutzfeldt-Jakob disease (vCJD), sporadic fatal insomnia (sFI), bovine spongiform encephalopathy (BSE), and Nor98 in sheep, have been identified in the last 10 years. In Japan, the number of iatrogenic CJD (iCJD) patients has been increasing, with the number of cases exceeding 100 by 2008, and BSE was recently identified adding to concerns regarding these diseases and their spread (Watts et al. 2006) .
Diagnosis of sporadic CJD (sCJD) is based on neurological findings, Periodic sharp wave complexes (PSWCs) observed on an electro-encephalograph (EEG), and the presence of 14-3-3 protein in the cerebrospinal fluid (CSF) are considered reliable diagnostic markers for CJD (Brandel et al. 2000) . Both of these measures are included in the diagnostic criteria for CJD supplied by the World Health Organization (WHO) (Brandel et al. 2000) .
Previously reported CSF biomarkers for CJD include 14-3-3 protein, total tau (t-tau) protein, and S-100 protein.
CSF levels of 14-3-3 protein and t-tau protein are influenced by neuronal loss, making them useful in the diagnosis of classical CJD, while S-100 protein levels in the CSF are influenced by activation of astrocytes and subsequent astrocytic gliosis, making it useful for the diagnosis of atypical CJD. Thus, many of the previously reported biomarkers for CJD reflect only one aspect of the disease, and there is a need to identify new biomarkers for CJD that reflect both the neuronal loss and the astrocytic gliosis. The analysis of CSF biomarkers in CJD patients can be a lengthy process and is associated with the risk of spreading the infectious particles. Indeed, Orru et al. (2009) showed the presence of abnormal prion protein (PrP Sc ) in the CSF of individuals with human variant CJD, revealing the possibility of infectious particles in human CSF.
Therapies such as cerebroventricular infusion of pentosan polysulfate or orally administered quinacrine or flupirtine have recently been shown to be effective in patients with human prion diseases, including CJD. However, a clinical study of quinacrine in patients with human prion disease found that it did not significantly affect the clinical course (Collinge et al. 2009 ). Geschwind (2009) reported that clinical trials for human prion disease are difficult because sCJD patients usually die within 6 months of disease onset, with many succumbing within the first 2 weeks after diagnosis. Thus, CJD patients should be treated immediately following diagnosis, and should not have to wait for extended periods of time for the results of a diagnostic test, highlighting a need for a simple and fast screening test.
The purpose of this study was to identify new CSF biomarkers for CJD in CSF using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Three new markers were identified by comparing CSF samples from CJD patients with those from healthy subjects. One of these markers was identified as fatty acid binding protein (FABP) . FABP proteins comprise a family of small, highly conserved, cytosolic 14-15 kDa proteins, which are involved in fatty acid transport and metabolism. Four FABPs specifically distributed in the CNS have been described: myelin FABP, brain FABP, epidermal FABP, and heart-type FABP (H-FABP) (Owada et al. 1996) . Because human H-FABP is an early plasma marker for acute myocardial infarction (AMI), we hypothesized that H-FABP could also indicate brain injury in CJD-infected patients.
We analyzed H-FABP levels in the CSF of CJD patients using an ELISA, the sensitivity and specificity of which were 90.3% and 92.9%, respectively. High concentrations of H-FABP were seen even in CSF samples from CJD patients with undetectable levels of 14-3-3 protein and low levels of t-tau protein (\1300 pg/ml: CJD cut-off data).
Recently, Hiura et al. (2005) reported the development of a new kit (Rapicheck Ò H-FABP) allowing the rapid estimation of H-FABP levels in serum. Rapicheck Ò H-FABP consists of a one-step immunochromatography system and a rapid semi-quantitative test for human H-FABP. Rapicheck Ò H-FABP was developed for the detection of cardiac damage and the diagnosis of AMI. Using this kit, we analyzed H-FABP levels in CSF samples from CJD patients, achieving a sensitivity and specificity of 87.9% and 96.0%, respectively. Thus, H-FABP represents a new biomarker for CJD and Rapicheck Ò H-FABP represents an economic diagnostic tool to aid in the early diagnosis of this disease.
Methods

Subjects
Patients with suspected CJD were recruited from the hospitals all over Japan for the purpose of biochemical assays on CSF. From more than 300 requests, we were able to perform a follow-up study of 124 patients with CJD, as determined by DWI. We classified the cases as sCJD (n = 114), familial CJD (n = 7; five cases resulting from a V180I mutation in the prion protein gene and two cases resulting from an M232R mutation in the prion protein gene), or iCJD (dura-associated CJD; n = 3).
For the control data, we collected CSF samples from 87 patients who suffered from one of the following disorders: dementia of Alzheimer's type (DAT) (n = 54; male = 33, female = 21), cerebrovascular disorders (CVD) (n = 7; male = 5, female = 2), Pick's disease (n = 1; male), Parkinson's disease (PD) (n = 5; male = 4, female = 1), corticobasal degeneration (CBD) (n = 2; both female), Huntington's disease (n = 1; male), frontotemporal dementia (FTD) (n = 1; male), progressive supranuclear palsy (PSP) (n = 3; male = 2, female = 1), Wernicke's encephalopathy (n = 2; both male), limbic encephalitis (n = 3; male = 1, female = 2), amyotrophic lateral sclerosis (ALS) (n = 4; male = 2, female = 2). We also obtained CSF from four healthy volunteers (n = 4; male = 2, female = 2) ( Table 1) .
The numbers of patients of each type are shown in Table 1 . This study was approved by the Medical Ethics Committee of Nagasaki University School of Medicine and the participants provided written informed consent.
2D-PAGE and Protein Identification
CSF samples from CJD patients and healthy, neurologically intact patients were compared by 2D-PAGE to detect differentially expressed proteins. CSF from deceased patients was obtained at autopsy, and all patients were definite cases of CJD. CSF samples were collected by routine lumbar puncture. The samples were analyzed on 2D-PAGE gels as previously described (Cepek et al. 2007 ). Briefly, CSF proteins (45 lg) were mixed with 10 ll of 10% SDS w/v/2.3% dithioerythritol (DTE) w/v, which had previously been heated to 95°C for 5 min.
The 2D-PAGE was performed according to Laemmli (1970) using sample buffer produced by BioRad (CO, USA) and SDS polyacrylamide gels consisting of 12% (w/v) total acrylamide monomer. The focused gel strips were laid onto the top of the polymerized SDS gels and covered by a low-melting point agarose buffer [1% (w/v) low-melting agarose, 0.25% SDS, 0.36 M bis-tris, 0.16 M bicine, trace bromphenol blue], which had previously been heated to melting temperature. After polymerization, gels were run in pairs at 24 mA/gel at constant current at room temperature.
Gel Staining and Analysis
Proteins were detected by silver staining according to Rabilloud's methods (Rabilloud 1999) . Stained gels were scanned and the image files were imported to the analysis software Imagemaster 3.1 (Amersham Biosciences).
Detection of the c-Isoform of 14-3-3 Protein and t-tau Protein in CSF Samples CSF samples were collected, aliquoted, and stored at -80°C until further use. All assays were performed simultaneously to avoid repeated freezing and thawing. Immunoassays for 14-3-3 protein in CSF were performed as previously described (Orru et al. 2009; Owada et al.; 1996; Hiura et al. 2005) . Polyclonal antibodies specific for the c-isoform of 14-3-3 protein were obtained from Immuno-Biological Laboratories (IBL) (18647; Gunma, Japan) and used at a dilution of 1:5000. All samples were analyzed using the same antibody to ensure comparable sensitivities. Protein detection was performed using an enhanced chemiluminescence detection kit (Amersham Buchler Company). Detection of t-tau protein in CSF samples was performed as previously described (Satoh et al. 2010 (Satoh et al. , 2007a .All assays were performed by two independent researchers. Fig. 1a ) and placed onto the designated section of the test plate. The plate was incubated at room temperature for 15 min. We performed the Rapicheck Ò H-FABP assay according to the method described in a previously published report (Hiura et al. 2005) . The appearance of an indicator test line (in addition to the quality control line) within 5 min was graded as ?3 (strongly positive); appearance of a test line within 15 min was graded as ?2 (moderately positive); and the appearance of a weak test line within 15 min was graded as ?1 (weakly positive). The absence of a test line at 15 min was reported as 0 (negative). All assays were performed by two independent researchers (Supplementary Fig. 1b) .
Immunohistochemistry
Immunohistochemistry was performed on 11 samples of brain tissue (frontal lobe, temporal lobe, occipital lobe, parietal lobe basal ganglia, caudate head, midbrain, pons, medulla, cerebellar lobules and dentate nucleus) from five patients with sCJD. Brain tissue was fixed with 20% buffered formalin. Multiple tissue blocks were immersed in 95% formic acid overnight, and then embedded in paraffin. Histological examination was performed on 5-mm-thick sections. Selected sections were immunostained using the avidinbiotin-peroxidase complex (ABC) method (Vector, Burlingame, CA, USA) with diaminobenzidine as the chromogen. After incubation for 60 min at room temperature with anti-H-FABP antiserum (dilution, 1:1000), anti-3F4 antiserum (dilution, 1:1000), which detects abnormal prion protein, and anti-S-100 protein antiserum (dilution, 1:5000), which detects astrocytes, an immunoperoxidase technique using a biotinylated goat anti-rabbit IgG as a secondary antibody and a peroxidase-conjugated avidin-biotin complex was performed according to the manufacturer's instructions (DAKO Co.). Peroxidase reactivity was then revealed using hydrogen peroxide and diaminobenzidine as a chromogenic substrate. As a control, preimmune serum from the immunized rabbit was used simultaneously on adjacent sections.
Statistical Analysis
We used SPSS version 11.0 software to perform all statistical analyses. Standard measures of diagnostic test validity were used to identify true-positive, true-negative, false-positive, and false-negative results. The H-FABP levels of 124 CJD patients and the remaining 87 patients with other diseases were used for these calculations (ROC analysis). The relationship between t-tau protein and H-FABP levels was statistically analyzed on the basis of Kendall and Spearman's coefficients using SPSS version 11.0 software.
Results
Analysis of 2D-PAGE Gels
To delineate proteins that are differentially present in the CSF of CJD patients (n = 4) and healthy subjects (n = 4), CSF samples were separated by 2D-PAGE and the levels of all detectable protein spots (107 spots) were compared between the groups (Fig. 1a) . All spots were analyzed using Image Master software (Amersham Bioscience) and manually revised. Three hundred and ten out of 107 spots were identified; of these, 69 were matched to a reference gel. Three spots were found to be elevated in the CSF of CJD patients compared with healthy subjects (Fig. 1b) . Fig. 1 a Silver-stained 2D-PAGE gel containing CSF proteins from CJD patients. Proteins were separated on the basis of size and charge. b Spots of higher intensity in CSF samples from CJD patients compared with CSF samples from healthy subjects. Thy-1 is transthyretin, so FABE and FABP represented epidermal fatty acid binding protein and fatty acid binding protein, respectively These spots of interest were excised for enzymatic cleavage and analysis by peptide mass fingerprinting using a MALDI-TOF mass spectrometer (PerSeptive Biosystems Voyager STR, Framingham, MA, USA). Proteins were identified by database searching. Two protein spots were identified as possibly being epidermal FABP (FABE), adipocytes FABP, and heart-type FABP (H-FABP). We did not identify the expression of FABP and adipocytes FABP in mouse brain (data not shown).
Analysis of 14-3-3 Protein and t-tau Protein Levels in CSF Samples CSF samples from 211 patients were assayed for the c-isoform of 14-3-3 protein. In the CJD group, 14-3-3 protein was detected in all CSF samples (124 patients). By comparison, 14-3-3 protein was detected in only two non-CJD patients with DAT, one patient with CVD, two patients with Wernicke's encephalopathy, and three patients with limbic encephalitis among the 87 otherwise healthy control subjects. The sensitivity and specificity of this assay for 14-3-3 protein in CJD patients were 82.2% and 90.8%, respectively (Fig. 4) .
CSF levels of t-tau protein were determined in 211 patients, and significant differences were observed among individuals (Table 1) . The level of t-tau protein was the greatest in the CJD group, ranging from 1,248 to 16,087 pg/ml (mean ± S.D. 7.174 ± 6.558 pg/ml). In the DAT group, t-tau protein levels ranged between 117 and 1,389 pg/ml (mean ± S.D. 387.37 ± 275.5 pg/ml). The CVD group showed levels similar to those in the DAT group, with a range of 172-1,300 pg/ml (mean ± S.D.: 623.4 ± 612.4 pg/ml). Therefore, compared with all other patients, CJD patients expressed higher levels of t-tau protein (P \ 0.01); their levels were also higher than those in the CVD and DAT groups specifically (P \ 0.05). (Table 1) The sensitivity and specificity of t-tau protein in CJD patients were 87.9% and 85.1%, respectively (Fig. 4) .
H-FABP ELISA of CSF Significant differences in H-FABP levels existed among the 12 groups of patients (Fig. 2a) . H-FABP levels were highest in the CJD group, with a range of 3,048-43,109 pg/ml (mean ± S.D. 11,798 ± 9,462 pg/ml) ( Fig. 2a, b ; Table 1 ). In comparison, the levels of H-FABP protein in the DAT group ranged from 1,975 to 5,723 pg/ml (mean ± S.D. 2786 ± 911 pg/ml). Compared with all other patients, CJD patients expressed higher levels of H-FABP (P \ 0.01), and their levels were also higher than those in the CVD and DAT groups specifically (P \ 0.05) (Fig. 2b) . Therefore, the cutoff value for the ELISA for H-FABP in CJD patients, determined by ROC analysis using SPSS version 11.0, was 3,500 pg/ml (Fig. 2c) . The sensitivity and specificity of H-FABP in CJD patients were 90.3% and 92.9%, respectively (Fig. 4) . We analyzed the CSF levels of 14-3-3 protein, t-tau protein, and H-FABP in 124 CJD patients. Altogether, 112 patients were found to be H-FABP-positive. Ninety-five patients with H-FABP-positive CSF were also positive for 14-3-3 protein and t-tau protein in the CSF. Five patients were negative for both of these proteins (Table 2) ; these patients included two sCJD cases and three familial CJD cases [resulting from a V180I mutation (Table 3) ]. We also analyzed chronological samples from 10 patients, revealing a gradual increase in H-FABP level as detected by ELISA ( Supplementary Fig. 2 a,b) . The chronological stages of CJD have not been clearly defined; therefore, we used the stages defined by Satoh et al. (2010 Satoh et al. ( , 2007a , as follows: the early stage was within 6 weeks of onset, the middle stage was from week 7 to the onset of akinetic mutism, and the end stage was after the onset of akinetic mutism.
Rapicheck Ò H-FABP Analysis of CSF Samples H-FABP protein levels in CSF samples from all 211 patients were measured using the Rapicheck Ò system, which detected H-FABP in all CJD patients (n = 124). In the non-CJD groups, the Rapicheck Ò system detected H-FABP protein in one patient with DAT, one with CVD, two with Wernicke's encephalopathy, and three with limbic encephalitis. All non-CJD patients positive for H-FABP using the Rapicheck Ò system showed high levels of H-FABP by ELISA. The sensitivity and specificity of H-FABP in CJD patients were 87.9% and 96.0%, respectively (Figs. 3, 4) . CJD is estimated to affect between 0.5 and 1.5 cases per million people per year; therefore most clinics would experience just 1-3 patients per year. The ELISA for H-FABP is an unsuitable method for clinical examinations because ELISA provides for the simultaneous processing of numerous CSF samples. Moreover, the price of ELISA for H-FABP for one patient or two patients is about one hundred times as expensive as that of the Rapicheck Ò H-FABP system. The Rapicheck Ò H-FABP system enables the assessment of one specimen at a time. As well, the Rapicheck Ò H-FABP system should be available in many hospitals in Japan because it is a useful and popular diagnostic kit for acute myocardial infarction and angina pectoris.
It is clear that ELISA for H-FABP is unsuitable for the small numbers of possible cases in small urban centers, places where the Rapicheck Ò H-FABP assay is more appropriate.
The cut-off level for the Rapicheck Ò H-FABP system was determined to be 6,200 pg/ml, approximately the same as that determined by Hiura et al (2005) . However, there are no reports of the relationship between the levels of CSF H-FABP detected by ELISA and those detected by Rapicheck Ò assay.
Neuropathological Analysis of H-FABP Staining in CJD Patient Brains
H-FABP protein expression was localized to neurons, astrocytes, and endothelial cells. Typical neuropathological findings in CJD patients included spongiform changes, neuronal loss in cerebral cortex, and moderate microglial activation. H-FABP immunohistochemistry revealed three notable features: staining was stronger in neurons surrounding lesions than in those from tissue lacking pathogenic lesions; reactive astrocytes that surrounded spongiform changes were positive for H-FABP ( Supplementary Fig. 4 ); and the distribution of H-FABP expression was similar to abnormal prion protein expression distribution. We assumed that these characteristics of H-FABP expression corresponded to direct or indirect protein-protein interactions between H-FABP and abnormal prion protein.
Correlation Between H-FABP ELISA and t-tau Protein Levels
The Kendall and Spearman's coefficients of correlation between the protein levels of t-tau and H-FABP were 0.374 and 0.263, respectively, revealing little correlation between the levels of t-tau protein and H-FABP as assessed by ELISA ( Supplementary Fig. 3a ).
Correlation Between H-FABP ELISA and S-100 Protein Levels
The Kendall and Spearman's coefficients of correlation between the protein levels of t-tau and H-FABP were 0.424 and 0.389, respectively, revealing little correlation between the levels of t-tau protein and H-FABP as assessed by ELISA ( Supplementary Fig. 3b ).
Discussion
The differential diagnosis of dementia is typically based on clinical criteria, while neurochemical data are rarely included in the diagnostic algorithms. In the case of sCJD, WHO has included the detection of CSF 14-3-3 protein in the diagnostic criteria. However, 14-3-3 protein is not always the best diagnostic marker for CJD because the sensitivity of assays for 14-3-3 protein is lower than that of assays for t-tau protein. Therefore, there is a need for a new diagnostic marker for CJD reflecting both the neuronal loss in the disease, as 14-3-3 protein and t-tau protein do, and the activation of microglia as S-100 protein does. The aim of this study was to investigate whether a proper diagnosis could be made using a disease-specific spot pattern on a 2D-PAGE gel. Three protein spots that were previously reported by Cepek et al. (2007) . were consistently and specifically expressed in the CSF of patients suffering from CJD. However, the present study focused on a single CJD-specific spot, which was identified as H-FABP (Fig. 1) . Our study was not enough in comparison with Cepek et al. (2007) and Brechlin et al.'s (2008) researches because we were not able to detect 107 spots but their research detected more than 2,000 spots. We detected some spots (14-3-3 protein, NSE, and LDH). Cepek et al. (2007) detected H-FABP in same method, but Fig. 1) . We clarified the relationships between H-FABP levels detected by ELISA and Rapicheck Ò H-FABP methods in the CSF of CJD patients. Both methods showed similar levels, and we identified similar abilities to accurately measure CSF H-FABP levels in the range 0-86,000 pg/ml Fig. 4 Correlation analysis of the positive CJD rate with 14-3-3 protein, total tau protein and S-100 protein using ELISA of H-FABP and Rapicheck Ò H-FABP methods Cell Mol Neurobiol (2010) 30:991-999 997 Brechlin et al. (2008) did not detect H-FABP. We thought that the reason was the depletion of protein or albumin in CSF at the step of pretreatment of 2D-PAGE. Guillaume et al. (2003) and Steinacker et al. (2004) have previously reported that H-FABP detection could therefore be helpful as a screening test for a pre-mortem diagnosis of the disease, and also to prevent the risk of iatrogenic transmission of CJD, but the function of H-FABP was not identified. However, the numbers of CJD patients and patients with other causes of rapid progressive dementia in these studies were insufficient for the authors to draw a definitive conclusion. ELISA kits for measuring H-FABP, 14-3-3 protein, and t-tau protein in the CSF are sufficiently sensitive (Tables 1, 2 ), but some cases that were negative for t-tau protein and 14-3-3 protein were positive for H-FABP (Table 3) ; therefore, we speculate that the combination of t-tau protein and H-FABP would be good diagnostic markers for prion disease.
To prove its value as a diagnostic marker for CJD, it is necessary to show that changes in H-FABP levels are associated with neuronal loss and astrocytic gliosis. CJD patients in the early stage of disease present with mild and moderate neuronal loss; therefore, Satoh et al. (Satoh 2007b) identified that t-tau protein and 14-3-3 protein levels in the CSF of CJD patients in the early stage of disease were not useful. Atypical cases of sCJD such as those with the MM2-cortical form or a V180I mutation causing familial CJD present with little neuronal loss and mild astrocytic gliosis. Therefore, there is a need for a biomarker reflecting both neuronal loss and mild astrocytic gliosis. H-FABP levels were not correlated with t-tau protein levels ( Supplementary Fig. 3a) . On the basis of neuropathologic and histologic examinations, t-tau expression was observed on the cytoskeletons of neurons, and t-tau protein levels detected by ELISA were correlated with neuronal loss. Changes in H-FABP levels did not always reflect only neuronal loss, because H-FABP ELISA concentrations did not correlate with t-tau protein concentrations (Spearman's rank correlation coefficient 0.263; Kendall's coefficient 0.374) (Supplementary Fig. 3a ). H-FABP levels were not correlated with S-100 protein levels ( Supplementary  Fig. 3b ). On the basis of neuropathologic and histologic examinations, S-100 protein expression was observed on astrocytes, and S-100 protein levels as detected by ELISA were correlated with astrocytic gliosis or activated astrocytes. H-FABP immunostaining was observed on neurons, activated astrocytes, and endothelial cells; however, 14-3-3 and t-tau protein expression was visible only in neurons. In addition, high H-FABP concentrations were associated with a low t-tau protein levels. Neuropathological findings revealed that neurons and astrocytes expressed H-FABP; however, neuronal 14-3-3 and t-tau staining patterns differed from H-FABP staining characteristics.
Rapicheck
Ò H-FABP analysis of CSF samples made up for the shortcomings of the ELISAs. Because the Rapicheck Ò H-FABP assay is a one-step immunochromatography method, it has the advantage of providing results within 15 min and allows for individual measurements of H-FABP levels. Therefore, costs were minimized and the risk of infection by abnormal prion proteins was reduced.
H-FABP levels might reflect disease stage: ELISA H-FABP has the possibility of being a chronological marker reflecting the time course of the clinical condition ( Supplementary Fig. 1 a,b) . Moreover, CSF H-FABP is a useful diagnostic marker for atypical cases of CJD. The atypical cases of CJD that were negative for 14-3-3 protein and had low levels (\1,300 pg/ml; cut-off data) of t-tau protein were positive ([3,200 pg/ml; cut-off data) for H-FABP by ELISA ( Table 2 ). The atypical cases of CJD had lower levels of t-tau protein, so the extent of neuronal loss in atypical cases of CJD was smaller than in typical and classical cases of CJD. H-FABP is therefore more useful as a diagnostic marker than 14-3-3 protein and t-tau protein in atypical cases of CJD. Collectively, our results show that H-FABP is a useful diagnostic marker in CJD patients.
